Profile data is unavailable for this security.
About the company
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.
- Revenue in USD (TTM)0.00
- Net income in USD-20.84m
- Incorporated1980
- Employees25.00
- LocationLisata Therapeutics Inc110 Allen Road, Second FloorBASKING RIDGE 07920United StatesUSA
- Phone+1 (908) 229-2590
- Fax+1 (845) 818-3588
- Websitehttps://www.lisata.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRX Pharmaceuticals Inc | 0.00 | -30.16m | 22.02m | 2.00 | -- | -- | -- | -- | -2.95 | -2.95 | 0.00 | -0.1398 | 0.00 | -- | -- | -- | -182.00 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Zivo Bioscience Inc | 27.65k | -7.78m | 22.14m | 8.00 | -- | -- | -- | 800.85 | -4.62 | -4.62 | 0.0163 | -0.9259 | 0.0206 | -- | -- | 3,456.25 | -580.66 | -376.60 | -- | -- | 41.99 | -- | -28,127.23 | -96,315.32 | -- | -97.39 | -- | -- | -- | -- | 11.07 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 39.55m | -6.28m | 22.40m | 91.00 | -- | 0.7537 | -- | 0.5663 | -0.4448 | -0.4448 | 2.75 | 2.10 | 0.4528 | 0.8383 | 3.45 | 434,643.10 | -7.25 | -7.03 | -10.66 | -9.52 | 84.66 | 79.95 | -16.01 | -17.64 | 1.11 | -25.08 | 0.3041 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.28m | 23.05m | 16.00 | -- | -- | -- | -- | -0.7625 | -0.7625 | 0.00 | -0.1219 | 0.00 | -- | -- | 0.00 | -207.24 | -- | -395.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.59 | -- | -- | -- |
| Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 23.66m | 20.00 | -- | -- | -- | 1,820.12 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
| Lisata Therapeutics Inc | 0.00 | -20.84m | 23.68m | 25.00 | -- | 0.4824 | -- | -- | -2.58 | -2.58 | 0.00 | 5.91 | 0.00 | -- | -- | 0.00 | -32.63 | -45.97 | -36.16 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Sol Gel Technologies Ltd | 1.55m | -27.24m | 23.69m | 36.00 | -- | 0.613 | -- | 15.24 | -1.02 | -1.02 | 0.0574 | 1.39 | 0.0338 | -- | 0.3774 | 43,166.67 | -59.27 | -31.60 | -64.80 | -35.49 | -- | -- | -1,752.77 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Polypid Ltd | 0.00 | -23.87m | 23.70m | 59.00 | -- | -- | -- | -- | -19.44 | -19.44 | 0.00 | -1.27 | 0.00 | -- | -- | 0.00 | -115.45 | -76.92 | -187.15 | -89.61 | -- | -- | -- | -- | -- | -24.61 | 1.25 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Lumos Pharma Inc | 2.05m | -34.03m | 24.02m | 33.00 | -- | 0.8784 | -- | 11.71 | -4.19 | -4.19 | 0.2526 | 3.37 | 0.0363 | -- | 9.47 | 62,151.52 | -60.27 | -29.78 | -68.62 | -32.32 | -- | -- | -1,659.39 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -40.16m | 24.04m | 42.00 | -- | 1.67 | -- | -- | -1.89 | -1.89 | 0.00 | 0.5242 | 0.00 | -- | -- | 0.00 | -103.63 | -- | -128.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
| bioAffinity Technologies Inc | 2.53m | -7.94m | 24.07m | 75.00 | -- | 4.04 | -- | 9.50 | -0.9036 | -0.9036 | 0.2895 | 0.5168 | 0.2482 | 144.95 | 6.16 | 33,766.67 | -77.80 | -- | -93.28 | -- | 31.26 | -- | -313.41 | -- | 1.76 | -- | 0.1983 | -- | 52,660.42 | -- | 2.66 | -- | -- | -- |
| Qilian International Holding Group Ltd | 46.47m | -7.78m | 24.23m | 298.00 | -- | 0.5663 | -- | 0.5214 | -0.2176 | -0.2176 | 1.30 | 1.20 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Bullfrog AI Holdings, Inc. | 65.00k | -5.36m | 24.49m | 4.00 | -- | 7.34 | -- | 376.83 | -0.9042 | -0.9042 | 0.0108 | 0.4253 | 0.0455 | -- | -- | 16,250.00 | -374.94 | -- | -- | -- | 92.00 | -- | -8,239.82 | -- | -- | -67.87 | 0.00 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Lipocine Inc | -2.85m | -16.35m | 25.03m | 17.00 | -- | 1.22 | -- | -- | -3.11 | -3.11 | -0.5417 | 3.83 | -0.0942 | -- | -- | -167,695.30 | -54.02 | -39.32 | -58.16 | -45.87 | -- | -- | -- | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Nymox Pharmaceutical Corp | 0.00 | -4.87m | 25.18m | 3.00 | -- | -- | -- | -- | -0.0536 | -0.0536 | 0.00 | -0.0204 | 0.00 | -- | -- | -- | -255.75 | -264.40 | -- | -464.48 | -- | -- | -- | -13,001.67 | -- | -42.44 | -- | -- | -- | -- | 47.55 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Lisata Therapeutics Inc's reporting currency: US Dollar USD
8.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 31 Mar 2024 | 284.67k | 3.43% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 175.93k | 2.12% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 97.22k | 1.17% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 56.25k | 0.68% |
| Geode Capital Management LLCas of 31 Dec 2023 | 43.39k | 0.52% |
| G1 Execution Services LLCas of 31 Dec 2023 | 33.75k | 0.41% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 14.35k | 0.17% |
| Citadel Securities LLCas of 31 Dec 2023 | 14.13k | 0.17% |
| Cook Wealth Management Group LLCas of 31 Dec 2023 | 12.18k | 0.15% |
| HighTower Advisors LLCas of 31 Dec 2023 | 10.04k | 0.12% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
